April 28, 2022
Translink Corporate Finance in Germany advised pharma-insight on the 100% sale to M3 Inc. pharma-insight delivers a comprehensive portfolio of market research services to the life sciences industry. This includes access to their dedicated healthcare panel, the addition of which further strengthens M3’s proprietary healthcare professional panel, which is the largest in the world.
Pharma-insight works closely with target groups across the life sciences and healthcare industries, offering services complementing a full range of qualitative and quantitative methodologies. Their in-depth market knowledge and consultancy offers new perspectives and approaches for their significant client roster.
The acquisition, which follows the recent acquisition of Australia’s Ekas in December 2021, and evidences M3’s strategy for aggressive global growth, further strengthens M3’s European presence, with pharma-insight’s dedicated German call centre, and coverage in Germany, UK, France, Denmark, Netherlands, Norway, Austria, Italy, Poland, Switzerland, Spain, and Czech Republic, alongside M3’s capabilities in US, Canada, Brazil, China, Japan, and South Korea.
Translink Corporate Finance is an independent partnership of firms dedicated to Corporate Finance and M&A advisory services across 35+ countries in the key markets in Europe, North and South America, Asia, Australia, and Africa. Translink has been successful in advising clients on thousands of transactions since its founding in 1972 and Translink offices have acted as advisers in over 100 M&A projects during the last twelve months.
Translink Corporate Finance GmbH & Co. KG with its offices in Frankfurt and Bremen covers Translink’s business in Germany and Austria. It is composed of seasoned finance and M&A professionals who have in-depth experience in a variety of sectors and disciplines.
Contact our Team Members advising in this transaction:
